A61K 31/396
Having three-membered rings
Official title: having three-membered rings, e.g. aziridine
A61K31/396 (Having three-membered rings) appears on 56 US grants and 92 published applications in this corpus.
Search patents in A61K- Granted patents
- 56
- Published applications
- 92
- Assignees
- 74
- Inventors
- 245
- Latest grant
- 16 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2001 | 1 | 0 |
| 2002 | 1 | 0 |
| 2003 | 2 | 3 |
| 2004 | 1 | 3 |
| 2005 | 0 | 1 |
| 2006 | 2 | 3 |
| 2007 | 1 | 5 |
| 2008 | 0 | 1 |
| 2009 | 0 | 5 |
| 2010 | 2 | 4 |
| 2011 | 2 | 3 |
| 2012 | 1 | 1 |
| 2013 | 3 | 4 |
| 2014 | 1 | 5 |
| 2015 | 3 | 4 |
| 2016 | 5 | 6 |
| 2017 | 3 | 4 |
| 2018 | 2 | 7 |
| 2019 | 3 | 4 |
| 2020 | 5 | 7 |
| 2021 | 4 | 7 |
| 2022 | 5 | 7 |
| 2023 | 3 | 0 |
| 2024 | 2 | 2 |
| 2025 | 2 | 3 |
| 2026 | 2 | 3 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Urea, amide, and substituted heteroaryl compounds for CBL-B inhibition16 Jun 2026US 12,653,809 B2Nurix Therapeutics, Inc.
- Methods for treating cardiac valve disease14 Apr 2026US 12,599,608 B2The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Gladstone
- Compounds and methods for CD73 modulation and indications therefor30 Dec 2025US 12,509,444 B2Plexxikon Inc.
- Method for treatment of pancreatitis16 Dec 2025US 12,496,309 B2Novmetapharma Co., Ltd.
- Pharmaceutical composition for treating fibrosis24 Sep 2024US 12,098,129 B2LTT Bio-Pharma Co., Ltd.
- Enhanced adoptive cell therapy16 Jul 2026US 2026/0199433 A1Werewolf Therapeutics, Inc.
- Modulators of rar related orphan receptors (rors)21 May 2026US 2026/0137650 A111949098 Canada Inc.
- Antimicrobial combinations9 Apr 2026US 2026/0097045 A1Helperby Therapeutics Limited
- Small Molecule Allosteric Modulators of Serotonin (5-HT) 5-HT2C and 5-HT2A Receptors17 Jul 2025US 2025/0230125 A1
- An oxaziridine platform for targeting functional allosteric methionine sites26 Jun 2025US 2025/0206708 A1Novartis AG
Most cited
By later US patents
- Composition for enzyme inhibition54US 7,737,112 B2Onyx Therapeutics, Inc. · 2010
- Treating red blood cell solutions with anti-viral agents39US 6,177,441 B1Cerus Corporation · 2001
- Treatment using herpes simplex virus34US 7,897,146 B2Crusade Laboratories Limited · 2011
- Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease25US 8,389,517 B2Genzyme Corporation · 2013
- Methods and compositions for inactivating viruses16US 6,369,048 B1V. I. Technologies, Inc. · 2002